WednesdaySep 28, 2022 2:02 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Activates First European Sites for Potentially Pivotal Clinical Trial

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. According to the update, the first European clinical trial sites in France and Spain are now open and actively enrolling patients. “Our primary focus continues to be on advancing the clinical development of…

Continue Reading

WednesdaySep 28, 2022 1:50 pm

QualityStocksNewsBreaks – Knightscope Inc. (NASDAQ: KSCP) Robot Roadshow Makes Ohio Stop

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, is slated for a visit in New Albany, Ohio, on Sept. 29, 2022. The company’s Robot Roadshow is a creative event designed to provide hands-on experiences for those interested in its Autonomous Security Robots (“ASRs”). The unique event is an engaging experiential event for potential clients that grabs attention, forges direct connections and sparks conversations. So far, the roadshow has made 59 stops in 23 states and Washington, DC. The event features a tour of Knightscope’s crime-fighting robots. The robots travel in a space-age,…

Continue Reading

WednesdaySep 28, 2022 1:25 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Clinical Trial for PRV-002

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the completion of all cohorts for its Phase I Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”) clinical trial. Odyssey’s trial involved administering its novel drug to treat concussion, PRV-002, to healthy human subjects. The drug was safe and well tolerated throughout the trial. “After reviewing the data from each of the cohorts, I have strong confidence that it is safe to proceed to the next clinical trial phase where PRV-002 will be administered for 10 consecutive days to subjects following concussion,” said Dallas…

Continue Reading

WednesdaySep 28, 2022 12:07 pm

QualityStocksNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Technology Enabling 12-Lead ECG Receives Patent from USPTO

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has been granted a patent from the United States Patent and Trademark Office (“USPTO”). The patent covers proprietary technology that allows the HeartBeam AIMIGo(TM) credit card-sized device to enable a 12-lead ECG anytime or anywhere. According to the announcement, the innovative tech and AIMIGo device makes it possible for a patient to record signals outside of a medical setting with a diagnostic synthesized 12-lead ECG that is immediately transmitted to a physician for review and diagnosis; the now-patented…

Continue Reading

WednesdaySep 28, 2022 11:55 am

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) to Focus on Launch of Proprietary UST Processing Method in Emerging Growth Conference Presentation

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food and beverage, and other key industries, is presenting at today’s Emerging Growth Investor Conference. The conference has built a reputation for being an effective way for publicly traded companies to present and communicate new products and services as well as other major announcements to thousands of individual and institutional investors and investment advisors and analysts. PBI president and CEO Richard T. Schumacher spoke at 9 a.m. ET; the focus of…

Continue Reading

WednesdaySep 28, 2022 11:24 am

QualityStocksNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Releases New Info about Upcoming Mullen Five RS

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, announced an upcoming version of its Mullen Five crossover that delivers a performance “to rival Plaid versions of Tesla’s Model S and Model X.” The Mullen Five was originally meant to compete against Tesla’s Model Y and Volkswagen ID.4, but the new version features more than 1,000 horsepower and the ability to go from 0 to 60 in under 2 seconds with a top speed of more than 200 mph; the new model also features an 800-volt electrical system, enabling rapid charge times when using a DC fast charger. The…

Continue Reading

WednesdaySep 28, 2022 11:15 am

DGE 6th Digital Strategy & Innovation For Medical Affairs Summit

Life science and health care professionals, as well as consumers, are invited to attend the 6th Digital Strategy & Innovation for Medical Affairs Summit on November 2-3, 2022. Participating pharma and medical companies can learn how to streamline their medical department affairs using innovative digital transformation policies that experts share and discuss at the DGE event.  The event is organized by Dynamic Global Events (“DGE”), a leading life science B2B event organizing company. The 6th Digital Strategy Summit is the largest event devoted to the medical industry that is being streamed live on an established interactive platform. The event will…

Continue Reading

WednesdaySep 28, 2022 10:30 am

DX3 USA 2022 – The Retail, Marketing and Technology Event Forays Into US Territories

Join thought leaders and dignitaries from the retail, marketing, and tech industries, as they offer important insights, with workshops, on how the retail and marketing sector should embrace the evolving technologies. Discover innovative solutions at the DX3 USA 2022 on October 3-4, 2022, being live streamed as a live streaming virtual event. DX3 is a leading event management enterprise organizing conferences and trade shows that bring industries, executives, and professionals from the retail, marketing, and technology fields together in a common forum. Having proven its mettle in Canada for 11 years, DX3 now enters the US markets to define, understand,…

Continue Reading

WednesdaySep 28, 2022 9:45 am

Rising Mortgage Lender REZYFi, Inc. Weathering Difficult Economy with Plans for Nationwide Expansion, Cannabis Industry Lending in Coming Months

REZYFi, a Miami-based mortgage lender, servicing traditional and non-traditional loans, is expanding its operations as part of a strategy to weather recent interest rate-affected market challenges REZYFI’s two wholly owned subsidiaries, REZYFi Lending and ResMac Inc., work through a network of independent brokers and proprietary technology to service home owners as well as corporate clients REZYFi expects to grow from more than 30 states where it is licensed to holding a licensing in every state The company is also preparing to launch a high-margin cannabis commercial real estate lending division later this year Emerging mortgage lender company REZYFi (stylized as…

Continue Reading

WednesdaySep 28, 2022 9:00 am

Odyssey Health, Inc.’s (ODYY) Brain-Related Drug Development Programs Taking Aim at Conditions with High Unmet Clinical Needs

Odyssey is a medical company focused on products that offer clinical advantages to unmet clinical needs Its brain-related drug development programs are currently focused on treatments for concussion and the Niemann Pick Type-C (“NPC”) disease, both of which do not currently have approved treatments The company is also developing medical devices such as the intranasal drug delivery device, CardioMap, and Save-A-Life Scientists and specialists describe concussion, which is also referred to as mild traumatic brain injury (“mTBI”), as a spectrum. On the one hand, some concussed patients fully recover and do not require medical intervention or attention; on the other,…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered